Sign In
Buy AUPH
$15.67
+0.280 (+1.82%)
At Close: Jun 03, 2026
Aurinia Pharmaceutical Stock Showing A Potential Reversal Pattern: 4 Key Levels To Watch
06:35pm, Tuesday, 20'th Apr 2021
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) was trending Tuesday afternoon possibly amid the stock making a new 52-week low. Below are the technical levels to watch on the chart.
Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
06:05am, Thursday, 15'th Apr 2021
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate i
Aurinia's Lupkynis Shows Treatment Benefit In Lupus Nephritis, Additional Efficacy Data Shows
07:38am, Thursday, 08'th Apr 2021
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has presented additional efficacy data from the AURA-LV and AURORA 1 trials of Lupkynis (voclosporin) in lupus nephritis (LN). Aurinia shared the data a
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented additional efficacy data from the AURA-LV
Aurinia Stock Has Great Potential, but It's Not a Buy Right Now
09:24am, Wednesday, 07'th Apr 2021
AUPH stock still has to prove its Lupus drug can sell and its price and the competition make that an unclear proposition. The post Aurinia Stock Has Great Potential, but It's Not a Buy Right Now appea
Aurinia Should Be A Long-Term Winner With Lupkynis Now On The Market
09:58am, Wednesday, 24'th Mar 2021
Aurinia saw its first product, Lupkynis, approved and launched in January, and analysts widely expect it to be a blockbuster. Despite completely removing regulatory risk from the picture, shares are e
Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report
06:05am, Monday, 15'th Mar 2021
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today announced a favorable assessment regarding the cost-
Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences
06:05am, Tuesday, 02'nd Mar 2021
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate i
Aurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q4 2020 Results - Earnings Call Transcript
11:03pm, Wednesday, 24'th Feb 2021
Aurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q4 2020 Results - Earnings Call Transcript
Is a Surprise Coming for Aurinia (AUPH) This Earnings Season?
09:54am, Tuesday, 23'rd Feb 2021
Aurinia (AUPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference
06:05am, Thursday, 18'th Feb 2021
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate i
Aurinia Pharmaceuticals: A Great Candidate For A Potential Buyout In 2021
03:03am, Thursday, 18'th Feb 2021
On January 22, the FDA approved Voclosporin to treat Lupus Nephritis. A label was included with a personal dosage protocol, which implies that VC will be protected against generics until 2037.
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021
06:05am, Wednesday, 17'th Feb 2021
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and year end 2020 financ
Aurinia Pharmaceuticals' Lupkynis Is Approved - 120%+ Potential Upside In 5 Years
03:57pm, Wednesday, 03'rd Feb 2021
Lupkynis is the first FDA-approved oral therapy for lupus nephritis. Approved label supports patented dosing protocol, which will last until 2037.
Aurinia Pharmaceuticals Is A Better Value Today At $17 Than It Was A Month Ago At $14
11:47am, Monday, 01'st Feb 2021
In the following, I review the recent FDA approval and label for LUPKYNIS and tease out some of the bullish implications. I then consider more factors in the comparison to competitor drug Benlysta.
